SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Baecklund Eva)
 

Sökning: WFRF:(Baecklund Eva) > Risk of serious inf...

  • Gron, KLKarolinska Institutet,Rigshosp, Denmark; Rigshosp, Denmark; Univ Copenhagen, Denmark,Karolinska Inst, Sweden (författare)

Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019-01-05
  • BMJ,2019

Nummerbeteckningar

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:141114855
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:141114855URI
  • https://doi.org/10.1136/annrheumdis-2018-214326DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-389881URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-158864URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Eva Baecklund ingår i gruppen The ARTIS Study Group.
  • Funding Agencies|NordForsk
  • To estimate (1) crude and age-and gender-adjusted incidence rates (IRs) of serious infections (SI) and (2) relative risks (RR) of SI in patients with rheumatoid arthritis (RA) initiating treatment with abatacept, rituximab or tocilizumab in routine care.MethodsThis is an observational cohort study conducted in parallel in Denmark and Sweden including patients with RA in Denmark (DANBIO) and Sweden (Anti-Rheumatic Treatment in Sweden Register/Swedish Rheumatology Quality Register) who started abatacept/rituximab/tocilizumab in 2010–2015. Patients could contribute to more than one treatment course. Incident SI (hospitalisations listing infection) and potential confounders were identified through linkage to national registries. Age- and gender-adjusted IRs of SI per 100 person years and additionally adjusted RRs of SI during 0–12 and 0–24 months since start of treatment were assessed (Poisson regression). Country-specific RRs were pooled using inverse variance weighting.ResultsWe identified 8987 treatment courses (abatacept: 2725; rituximab: 3363; tocilizumab: 2899). At treatment start, rituximab-treated patients were older, had longer disease duration and more previous malignancies; tocilizumab-treated patients had higher C reactive protein. During 0–12 and 0–24 months of follow-up, 456 and 639 SI events were identified, respectively. The following were the age- and gender-adjusted 12-month IRs for abatacept/rituximab/tocilizumab: 7.1/8.1/6.1 for Denmark and 6.0/6.4/4.7 for Sweden. The 24-month IRs were 6.1/7.5/5.2 for Denmark and 5.6/5.8/4.3 for Sweden. Adjusted 12-month RRs for tocilizumab versus rituximab were 0.82 (0.50 to 1.36) for Denmark and 0.76 (0.57 to 1.02) for Sweden, pooled 0.78 (0.61 to 1.01); for abatacept versus rituximab 0.94 (0.55 to 1.60) for Denmark and 0.86 (0.66 to 1.13) for Sweden, pooled 0.88 (0.69 to 1.12); and for abatacept versus tocilizumab 1.15 (0.69 to 1.90) for Denmark and 1.14 (0.83 to 1.55) for Sweden, pooled 1.13 (0.91 to 1.42). The adjusted RRs for 0–24 months were similar.ConclusionFor patients starting abatacept, rituximab or tocilizumab, differences in baseline characteristics were seen. Numerical differences in IR of SI between drugs were observed. RRs seemed to vary with drug (tocilizumab < abatacept < rituximab) but should be interpreted with caution due to few events and risk of residual confounding.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Arkema, EVKarolinska Institutet,Karolinska Inst, Dept Med, Stockholm, Sweden (författare)
  • Glintborg, BRigshosp, DANBIO, Copenhagen, Denmark;Rigshosp, Ctr Head & Orthoped, Ctr Rheumatol & Spine Dis, Copenhagen Ctr Arthrit Res COPECARE, Copenhagen, Denmark;Copenhagen Univ Hosp, Gentofte & Herlev Hosp, Dept Rheumatol, Copenhagen, Denmark (författare)
  • Mehnert, FAarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark (författare)
  • Ostergaard, MRigshosp, DANBIO, Copenhagen, Denmark;Rigshosp, Ctr Head & Orthoped, Ctr Rheumatol & Spine Dis, Copenhagen Ctr Arthrit Res COPECARE, Copenhagen, Denmark;Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark (författare)
  • Dreyer, LAalborg Univ, Dept Clin Med, Aalborg, Denmark;Aalborg Univ, Dept Rheumatol, Aalborg, Denmark;Aalborg Univ Hosp, Aalborg, Denmark (författare)
  • Norgaard, MAarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark (författare)
  • Krogh, NSZiteLab ApS, Copenhagen, Denmark (författare)
  • Askling, JKarolinska Institutet,Karolinska Inst, Dept Med, Stockholm, Sweden;Karolinska Inst, Stockholm, Sweden (författare)
  • Hetland, MLRigshosp, DANBIO, Copenhagen, Denmark;Rigshosp, Ctr Head & Orthoped, Ctr Rheumatol & Spine Dis, Copenhagen Ctr Arthrit Res COPECARE, Copenhagen, Denmark;Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark (författare)
  • Askling, JKarolinska Institutet (författare)
  • Klareskog, LKarolinska Institutet (författare)
  • Feltelius, NKarolinska Inst, Sweden (författare)
  • Baecklund, Eva,1956-Uppsala universitet,Reumatologi,Uppsala Univ, Sweden(Swepub:uu)evaba786 (författare)
  • Sjöwall, ChristopherLinköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Reumatologiska kliniken i Östergötland(Swepub:liu)chrsj93 (författare)
  • Rantapaa-Dahlqvist, SUmea Univ, Sweden (författare)
  • Forsblad-d'Elia, HUmea Univ, Sweden (författare)
  • Jacobsson, LSahlgrens Acad, Sweden (författare)
  • Turesson, CLund Univ, Sweden (författare)
  • Lindqvist, ELund Univ, Sweden (författare)
  • Nisell, RSwedish Rheumatol Qual Register, Sweden (författare)
  • Karolinska InstitutetRigshosp, Denmark; Rigshosp, Denmark; Univ Copenhagen, Denmark (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Annals of the rheumatic diseases: BMJ78:3, s. 320-3271468-20600003-4967

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy